University Of Washington

Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.

For Laura Q.M. Chow, MD, medical oncologist at Seattle Cancer Care Alliance and professor of medicine in the division of medical oncology at the University of Washington, there is still much to be done to improve the quality of life and survival of patients with lung cancer until it is eradicated — starting with identification of better biomarkers to personalize therapy and development of novel therapies to improve response and survival in clinical trials.

As the COVID-19 pandemic intensifies across the United States, incidence among individuals with cancer remains relatively low.

ORLANDO — Patients with relapsed or refractory large B-cell non-Hodgkin lymphoma can be successfully treated and monitored in the outpatient setting with the chimeric antigen receptor T-cell therapy lisocabtagene maraleucel, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Higher total body irradiation dose appeared associated with significantly higher risk for nonrelapse mortality and overall mortality among patients with non-Hodgkin lymphoma who underwent reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.

In 1984, a teenage boy was lying in his hospital bed, his body ravaged by acute graft-versus host disease.

Patients who received allogeneic hematopoietic stem cell transplants between 2013 and 2017 demonstrated substantial improvement in survival outcomes and fewer complications than those who underwent transplantation a decade earlier, according to results of a retrospective study published in Annals of Internal Medicine.

The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to gemcitabine — the combination was planned based upon the positive results of the MPACT trial in the metastatic setting. Interestingly, around the same time as the MPACT trial, FOLFIRINOX also showed improved OS in the metastatic setting compared with single-agent gemcitabine. Although median survival with FOLFIRINOX appeared to be numerically superior than with gemcitabine and nab-paclitaxel, subsequent real-world analyses indicated no significant differences in OS or time to treatment failure between the two regimens. It is therefore surprising that although the adjuvant FOLFIRINOX study was positive, the adjuvant gemcitabine and nab-paclitaxel trial was not.

ORLANDO — The price of generic imatinib has decreased substantially in the United States over the past 2 years, according to a speaker at ASH Annual Meeting and Exposition.